• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, August 26, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Inhibiting cancer-causing protein could prevent scleroderma fibrosis

Bioengineer by Bioengineer
February 26, 2019
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

ANN ARBOR, Mich. – A protein known to play a role in cancer may also be increasing fibrosis in scleroderma patients.

Scleroderma, a rare, chronic autoimmune disease, is marked by hardening of the skin and internal organs. Symptoms often include pain, stiffness, fatigue and breathing difficulties.

“The disease creates excessive fibroblast activation that ultimately results in tissue damage and organ failure,” says Amr Sawalha, M.D., a professor in the Division of Rheumatology at the University of Michigan.

In a new study, published in Proceedings of the National Academy of Sciences, Sawalha and his team examined scleroderma at the molecular level to better understand the fibrosis process.

“We examined the molecule EZH2, which has been known to play a role in several types of cancer,” Sawalha says. “This protein regulates gene expression, by affecting modifications that happen to DNA and other proteins attached to DNA, through a process called epigenetic regulation.”

Sawalha and fellow researchers had previously identified a role for EZH2 in lupus, another autoimmune disease, flares.

“EZH2 is overexpressed in lupus T cells, which makes these white blood cells active in lupus patients,” he says. “We then expanded our studies to scleroderma and specifically looked at the role of EZH2 in fibroblasts and endothelial cells in this disease.”

Examining EZH2

The research team first isolated cells from scleroderma patients in collaboration with the Michigan Medicine Scleroderma Program. The program provides care for a large number of scleroderma patients at the University of Michigan. They then expanded their studies to animal models to further test findings identified in the human cells.

“Both increased fibrosis and abnormal blood vessel function, or defective angiogenesis, are major aspects of pathology in this autoimmune disease,” says Eliza Tsou, Ph.D., a research assistant professor at U-M and first author of the study. “We dissected the cells and found that increased levels of EZH2 were contributing to this disease process in scleroderma patients.”

After identifying the molecule, the research team examined what happened in the cells when EZH2 was inhibited.

“When we suppressed EZH2, we found we could correct increased fibrosis and abnormal blood vessel function in scleroderma,” Sawalha says.

Translating to the bedside

Because EZH2 is a molecule known to play a role in cancer patients, Sawalha says the ability to translate their laboratory work to patients may be easier.

“What is nice is that EZH2 inhibitors are already developed and in clinical trials in certain cancers,” he says. “Therefore, our findings can be more readily translated to the bedside by repurposing already existing inhibitors for EZH2 to treat scleroderma.”

As there are currently no effective treatment options for scleroderma, Sawalha notes that this type of research is important for future studies and trials.

“We will continue to research this disease at the molecular level and try to identify additional therapeutic targets for this patient population,” he says.

###

Media Contact
Kylie Urban
[email protected]

Related Journal Article

https://labblog.uofmhealth.org/lab-report/inhibiting-cancer-causing-protein-could-prevent-scleroderma-fibrosis
http://dx.doi.org/10.1073/pnas.1813006116

Tags: cancerInternal MedicineMedicine/Health
Share12Tweet7Share2ShareShareShare1

Related Posts

Spatial Cues Drive Multiplexed Theta Coding

August 26, 2025

BU Study Reveals How Type 2 Diabetes Blood Factors Fuel Breast Cancer Aggressiveness

August 26, 2025

Smart Virtual Screening for JAK3 Covalent Inhibitors

August 26, 2025

Educating on Inequality Boosts Women in Biomedical Engineering

August 26, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    147 shares
    Share 59 Tweet 37
  • Molecules in Focus: Capturing the Timeless Dance of Particles

    142 shares
    Share 57 Tweet 36
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    115 shares
    Share 46 Tweet 29
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    81 shares
    Share 32 Tweet 20

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Unseen Whirlwinds: Researchers Discover ‘Hidden’ Vortices That May Impact Soil and Snow Movement

Higher Skin Autofluorescence Signals Cancer Risk

Spatial Cues Drive Multiplexed Theta Coding

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.